A pilot study of paricalcitol plus nanoliposomal irinotecan and 5-FU/LV in advanced pancreatic cancer patients after progression on gemcitabine-based therapy.

Patrick M Grierson Rama Suresh Benjamin Tan Katrina S Pedersen Manik Amin Haeseong Park Nikolaos A Trikalinos Jingxia Liu Nicholas Boice Amberly Brown Sapana Bansod Andrea Wang-Gillam Kian-Huat Lim

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Paricalcitol at 7mcg/kg/week in combination with Nal-iri/ 5-FU/LV is safely tolerated, may increase tumor vascularity and warrants further investigation.

Keyphrases

stem cells
clinical trial
mesenchymal stem cells
rectal cancer
replacement therapy